Outlook Therapeutics posts $20.3m loss after approval

• Outlook Therapeutics reported a fiscal Q3 2026 net loss of $20.3 million after receiving FDA approval for LYTENAVA in July.
• OTLK shares were down about 19.2% at $0.89 in premarket trading following the results.
• The company plans to launch LYTENAVA in the U.S. before year-end 2026 and says annual U.S. sales could exceed $500 million by 2030.

Outlook Therapeutics (NASDAQ:OTLK) reported a fiscal Q3 net loss of $20.3 million as it prepares to launch FDA-approved wet AMD treatment LYTENAVA.

Revenue fell to $9,000 from $1.5 million a year earlier, while adjusted net loss improved to $10.9 million from $15.8 million.

“FDA approval of LYTENAVA marks a defining moment for Outlook Therapeutics,” said Outlook Therapeutics Chief Executive Officer Bob Jahr.

Outlook held $11.2 million in cash at June 30 and subsequently raised approximately $51.1 million net through a 55.6-million-share public offering.

Following the announcement, Outlook Therapeutics' share price was down 19.2% at approximately $0.89 in premarket trading.

The FDA approved LYTENAVA on July 24 as the only approved ophthalmic bevacizumab for wet AMD, with Outlook planning a U.S. launch before year-end.

Outlook is also commercializing LYTENAVA in Germany, Austria and the U.K., while planning a Netherlands launch in 2026 and Switzerland in 2027.